263 related articles for article (PubMed ID: 27747531)
1. Rituximab for Rheumatoid Arthritis.
Cohen MD; Keystone E
Rheumatol Ther; 2015 Dec; 2(2):99-111. PubMed ID: 27747531
[TBL] [Abstract][Full Text] [Related]
2. [RITUXIMAB IN RHEUMATOID ARTHRITIS - THERAPEUTIC ASPECTS BASED ON 18 YEARS OF GLOBAL EXPERIENCE].
Zisapel M; Paran D; Elkayam O
Harefuah; 2019 Sep; 158(9):595-600. PubMed ID: 31507112
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of rheumatoid arthritis: an update.
Mok CC
Drug Des Devel Ther; 2013 Dec; 8():87-100. PubMed ID: 24403823
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. Rituximab: in rheumatoid arthritis.
Frampton JE; Scott LJ
BioDrugs; 2007; 21(5):333-41: discussion 342. PubMed ID: 17896839
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure.
Solau-Gervais E; Prudhomme C; Philippe P; Duhamel A; Dupont-Créteur C; Legrand JL; Houvenagel E; Flipo RM
Joint Bone Spine; 2012 May; 79(3):281-4. PubMed ID: 21724444
[TBL] [Abstract][Full Text] [Related]
7. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
Boleto G; Avouac J; Wipff J; Forien M; Dougados M; Roux C; Kahan A; Dieude P; Allanore Y
Semin Arthritis Rheum; 2018 Oct; 48(2):149-154. PubMed ID: 29548542
[TBL] [Abstract][Full Text] [Related]
8. Update on the use of rituximab for intractable rheumatoid arthritis.
Looney RJ
Open Access Rheumatol; 2009; 1():83-94. PubMed ID: 27789983
[TBL] [Abstract][Full Text] [Related]
9. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence.
Looney RJ
Drugs; 2006; 66(5):625-39. PubMed ID: 16620141
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
11. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
Nurmohamed MT
Drugs; 2009 Oct; 69(15):2035-43. PubMed ID: 19791825
[TBL] [Abstract][Full Text] [Related]
12. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
13. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.
Wijesinghe H; Galappatthy P; de Silva R; Seneviratne SL; Saravanamuttu U; Udagama P; Hart M; Kelleher P; Senerath U; Fernandopulle R; Weerasekera LP; Wijayaratne LS
BMC Musculoskelet Disord; 2017 Jul; 18(1):310. PubMed ID: 28724365
[TBL] [Abstract][Full Text] [Related]
14. Safety of rituximab in rheumatoid arthritis.
Covelli M; Sarzi-Puttini P; Atzeni F; Macchioni P
Reumatismo; 2010; 62(2):101-6. PubMed ID: 20657886
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
Mease PJ; Cohen S; Gaylis NB; Chubick A; Kaell AT; Greenwald M; Agarwal S; Yin M; Kelman A
J Rheumatol; 2010 May; 37(5):917-27. PubMed ID: 20194448
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial.
Mariette X; Rouanet S; Sibilia J; Combe B; Le Loët X; Tebib J; Jourdan R; Dougados M
Ann Rheum Dis; 2014 Aug; 73(8):1508-14. PubMed ID: 23723317
[TBL] [Abstract][Full Text] [Related]
17. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
Porter D; van Melckebeke J; Dale J; Messow CM; McConnachie A; Walker A; Munro R; McLaren J; McRorie E; Packham J; Buckley CD; Harvie J; Taylor P; Choy E; Pitzalis C; McInnes IB
Lancet; 2016 Jul; 388(10041):239-47. PubMed ID: 27197690
[TBL] [Abstract][Full Text] [Related]
18. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.
van Vollenhoven RF; Emery P; Bingham CO; Keystone EC; Fleischmann R; Furst DE; Macey K; Sweetser M; Kelman A; Rao R
J Rheumatol; 2010 Mar; 37(3):558-67. PubMed ID: 20110520
[TBL] [Abstract][Full Text] [Related]
19. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]